The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).
about
Growth factor use in medication-induced hematologic toxicity.A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized OncologyRandomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management.G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease.Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.
P2860
Q33417812-343ABFF6-7F03-4AF2-AD88-8B143CDE5E87Q37091148-4A6F0E8F-1DC1-4697-9F6E-50428C788906Q37606891-F10A3FF9-5B74-40A4-B644-67C106817D13Q38256944-C365E823-C357-4DEE-8A87-B7F229A4F561Q38315396-C4044E56-0F1D-4865-9CF9-D4949652AEDFQ38468072-153D21D2-1F76-49B4-A7EE-62237699CE34Q38613025-D8EF7CD6-86CA-45C5-9E96-0D1ACCF2BDA0Q38689804-CAC9D82E-560C-4B1D-A931-B2DAA3FFA220Q38829906-76570F95-4089-4D97-BBCF-1E3CC9B63AF1Q38892537-DCE4407A-EB32-454B-853D-6FBC266536B4Q40147851-1163127A-D9E5-4958-81EB-7EA058E0A3A2Q40889689-FBF9AB1F-C666-4C72-A6E0-56721959AD9AQ41453238-1F04024D-63D2-42D6-B4DE-C94E147797DDQ48243713-D510C5DF-B96F-4621-8107-C21D24FF451FQ49937810-FFCC9078-A84E-4A12-A6BB-6A628D29BA3FQ50112937-F8CBF97E-B037-45ED-8D49-64D42B1EFC38Q55057566-339BA525-D782-46AE-A0ED-565DE32166BF
P2860
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The five "Ws" for bone pain du ...... stimulating factors (G-CSFs).
@en
type
label
The five "Ws" for bone pain du ...... stimulating factors (G-CSFs).
@en
prefLabel
The five "Ws" for bone pain du ...... stimulating factors (G-CSFs).
@en
P50
P1476
The five "Ws" for bone pain du ...... y stimulating factors (G-CSFs)
@en
P2093
Andrea Bellodi
P304
P356
10.1016/J.CRITREVONC.2013.08.006
P577
2013-08-29T00:00:00Z